- Home
- AUPH vs CMRE Comparison
AUPH vs CMRE Comparison
Compare AUPH & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- CMRE
- Stock Information
- Founded
- AUPH 1993
- CMRE 1974
- Country
- AUPH Canada
- CMRE Monaco
- Employees
- AUPH N/A
- CMRE N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- CMRE Marine Transportation
- Sector
- AUPH Health Care
- CMRE Consumer Discretionary
- Exchange
- AUPH Nasdaq
- CMRE Nasdaq
- Market Cap
- AUPH 1.4B
- CMRE 1.3B
- IPO Year
- AUPH 1999
- CMRE 2010
- Fundamental
- Price
- AUPH $12.83
- CMRE $12.73
- Analyst Decision
- AUPH Strong Buy
- CMRE Hold
- Analyst Count
- AUPH 3
- CMRE 1
- Target Price
- AUPH $12.00
- CMRE $13.00
- AVG Volume (30 Days)
- AUPH 1.5M
- CMRE 420.0K
- Earning Date
- AUPH 11-06-2025
- CMRE 10-31-2025
- Dividend Yield
- AUPH N/A
- CMRE 3.63%
- EPS Growth
- AUPH N/A
- CMRE N/A
- EPS
- AUPH 0.42
- CMRE 2.37
- Revenue
- AUPH $260,111,000.00
- CMRE $2,085,912,000.00
- Revenue This Year
- AUPH $16.92
- CMRE N/A
- Revenue Next Year
- AUPH $14.43
- CMRE N/A
- P/E Ratio
- AUPH $29.12
- CMRE $4.69
- Revenue Growth
- AUPH 25.59
- CMRE 56.37
- 52 Week Low
- AUPH $6.55
- CMRE $6.02
- 52 Week High
- AUPH $12.90
- CMRE $12.73
- Technical
- Relative Strength Index (RSI)
- AUPH 63.83
- CMRE 71.28
- Support Level
- AUPH $12.18
- CMRE $12.20
- Resistance Level
- AUPH $12.90
- CMRE $12.68
- Average True Range (ATR)
- AUPH 0.42
- CMRE 0.30
- MACD
- AUPH -0.06
- CMRE 0.01
- Stochastic Oscillator
- AUPH 92.89
- CMRE 97.32
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About CMRE Costamare Inc. $0.0001 par value
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.